Remission of Epstein-Barr virus-positive post-transplant lymphoproliferative disorder by conversion to everolimus in a kidney transplant recipient.
Identifieur interne : 000248 ( Main/Exploration ); précédent : 000247; suivant : 000249Remission of Epstein-Barr virus-positive post-transplant lymphoproliferative disorder by conversion to everolimus in a kidney transplant recipient.
Auteurs : Koji Nanmoku [Japon] ; Takahiro Shinzato [Japon] ; Taro Kubo [Japon] ; Toshihiro Shimizu [Japon] ; Takashi Yagisawa [Japon]Source :
- Transplant infectious disease : an official journal of the Transplantation Society [ 1399-3062 ] ; 2019.
Descripteurs français
- KwdFr :
- Complications postopératoires (traitement médicamenteux), Herpèsvirus humain de type 4 (MeSH), Humains (MeSH), Immunosuppresseurs (usage thérapeutique), Induction de rémission (MeSH), Infections à virus Epstein-Barr (traitement médicamenteux), Mâle (MeSH), Receveurs de transplantation (MeSH), Sujet âgé (MeSH), Syndromes lymphoprolifératifs (traitement médicamenteux), Syndromes lymphoprolifératifs (virologie), Transplantation rénale (effets indésirables), Évérolimus (usage thérapeutique).
- MESH :
- effets indésirables : Transplantation rénale.
- traitement médicamenteux : Complications postopératoires, Infections à virus Epstein-Barr, Syndromes lymphoprolifératifs.
- usage thérapeutique : Immunosuppresseurs, Évérolimus.
- virologie : Syndromes lymphoprolifératifs.
- Herpèsvirus humain de type 4, Humains, Induction de rémission, Mâle, Receveurs de transplantation, Sujet âgé.
English descriptors
- KwdEn :
- Aged (MeSH), Epstein-Barr Virus Infections (drug therapy), Everolimus (therapeutic use), Herpesvirus 4, Human (MeSH), Humans (MeSH), Immunosuppressive Agents (therapeutic use), Kidney Transplantation (adverse effects), Lymphoproliferative Disorders (drug therapy), Lymphoproliferative Disorders (virology), Male (MeSH), Postoperative Complications (drug therapy), Remission Induction (MeSH), Transplant Recipients (MeSH).
- MESH :
- chemical , therapeutic use : Everolimus, Immunosuppressive Agents.
- adverse effects : Kidney Transplantation.
- drug therapy : Epstein-Barr Virus Infections, Lymphoproliferative Disorders, Postoperative Complications.
- virology : Lymphoproliferative Disorders.
- Aged, Herpesvirus 4, Human, Humans, Male, Remission Induction, Transplant Recipients.
Abstract
Post-transplant lymphoproliferative disorder (PTLD) is a fatal complication of transplantation. There is no clear consensus on the treatment of PTLD. In most cases, the pathogenetic mechanism of PTLD involves the Epstein-Barr virus (EBV). We report the case of an elderly kidney transplant recipient who developed EBV-positive monomorphic T-cell PTLD 14 years after transplantation. Conversion from conventional immunosuppressants to everolimus induced complete remission of PTLD accompanied by a decrease in blood EBV-DNA level without chemotherapy.
DOI: 10.1111/tid.13116
PubMed: 31102475
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Remission of Epstein-Barr virus-positive post-transplant lymphoproliferative disorder by conversion to everolimus in a kidney transplant recipient.</title><author><name sortKey="Nanmoku, Koji" sort="Nanmoku, Koji" uniqKey="Nanmoku K" first="Koji" last="Nanmoku">Koji Nanmoku</name><affiliation wicri:level="1"><nlm:affiliation>Surgical Branch, Institute of Kidney Diseases, Jichi Medical University Hospital, Shimotsuke, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Surgical Branch, Institute of Kidney Diseases, Jichi Medical University Hospital, Shimotsuke</wicri:regionArea><wicri:noRegion>Shimotsuke</wicri:noRegion></affiliation></author><author><name sortKey="Shinzato, Takahiro" sort="Shinzato, Takahiro" uniqKey="Shinzato T" first="Takahiro" last="Shinzato">Takahiro Shinzato</name><affiliation wicri:level="1"><nlm:affiliation>Surgical Branch, Institute of Kidney Diseases, Jichi Medical University Hospital, Shimotsuke, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Surgical Branch, Institute of Kidney Diseases, Jichi Medical University Hospital, Shimotsuke</wicri:regionArea><wicri:noRegion>Shimotsuke</wicri:noRegion></affiliation></author><author><name sortKey="Kubo, Taro" sort="Kubo, Taro" uniqKey="Kubo T" first="Taro" last="Kubo">Taro Kubo</name><affiliation wicri:level="1"><nlm:affiliation>Surgical Branch, Institute of Kidney Diseases, Jichi Medical University Hospital, Shimotsuke, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Surgical Branch, Institute of Kidney Diseases, Jichi Medical University Hospital, Shimotsuke</wicri:regionArea><wicri:noRegion>Shimotsuke</wicri:noRegion></affiliation></author><author><name sortKey="Shimizu, Toshihiro" sort="Shimizu, Toshihiro" uniqKey="Shimizu T" first="Toshihiro" last="Shimizu">Toshihiro Shimizu</name><affiliation wicri:level="1"><nlm:affiliation>Surgical Branch, Institute of Kidney Diseases, Jichi Medical University Hospital, Shimotsuke, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Surgical Branch, Institute of Kidney Diseases, Jichi Medical University Hospital, Shimotsuke</wicri:regionArea><wicri:noRegion>Shimotsuke</wicri:noRegion></affiliation></author><author><name sortKey="Yagisawa, Takashi" sort="Yagisawa, Takashi" uniqKey="Yagisawa T" first="Takashi" last="Yagisawa">Takashi Yagisawa</name><affiliation wicri:level="1"><nlm:affiliation>Surgical Branch, Institute of Kidney Diseases, Jichi Medical University Hospital, Shimotsuke, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Surgical Branch, Institute of Kidney Diseases, Jichi Medical University Hospital, Shimotsuke</wicri:regionArea><wicri:noRegion>Shimotsuke</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2019">2019</date><idno type="RBID">pubmed:31102475</idno><idno type="pmid">31102475</idno><idno type="doi">10.1111/tid.13116</idno><idno type="wicri:Area/Main/Corpus">000270</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000270</idno><idno type="wicri:Area/Main/Curation">000270</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000270</idno><idno type="wicri:Area/Main/Exploration">000270</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Remission of Epstein-Barr virus-positive post-transplant lymphoproliferative disorder by conversion to everolimus in a kidney transplant recipient.</title><author><name sortKey="Nanmoku, Koji" sort="Nanmoku, Koji" uniqKey="Nanmoku K" first="Koji" last="Nanmoku">Koji Nanmoku</name><affiliation wicri:level="1"><nlm:affiliation>Surgical Branch, Institute of Kidney Diseases, Jichi Medical University Hospital, Shimotsuke, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Surgical Branch, Institute of Kidney Diseases, Jichi Medical University Hospital, Shimotsuke</wicri:regionArea><wicri:noRegion>Shimotsuke</wicri:noRegion></affiliation></author><author><name sortKey="Shinzato, Takahiro" sort="Shinzato, Takahiro" uniqKey="Shinzato T" first="Takahiro" last="Shinzato">Takahiro Shinzato</name><affiliation wicri:level="1"><nlm:affiliation>Surgical Branch, Institute of Kidney Diseases, Jichi Medical University Hospital, Shimotsuke, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Surgical Branch, Institute of Kidney Diseases, Jichi Medical University Hospital, Shimotsuke</wicri:regionArea><wicri:noRegion>Shimotsuke</wicri:noRegion></affiliation></author><author><name sortKey="Kubo, Taro" sort="Kubo, Taro" uniqKey="Kubo T" first="Taro" last="Kubo">Taro Kubo</name><affiliation wicri:level="1"><nlm:affiliation>Surgical Branch, Institute of Kidney Diseases, Jichi Medical University Hospital, Shimotsuke, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Surgical Branch, Institute of Kidney Diseases, Jichi Medical University Hospital, Shimotsuke</wicri:regionArea><wicri:noRegion>Shimotsuke</wicri:noRegion></affiliation></author><author><name sortKey="Shimizu, Toshihiro" sort="Shimizu, Toshihiro" uniqKey="Shimizu T" first="Toshihiro" last="Shimizu">Toshihiro Shimizu</name><affiliation wicri:level="1"><nlm:affiliation>Surgical Branch, Institute of Kidney Diseases, Jichi Medical University Hospital, Shimotsuke, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Surgical Branch, Institute of Kidney Diseases, Jichi Medical University Hospital, Shimotsuke</wicri:regionArea><wicri:noRegion>Shimotsuke</wicri:noRegion></affiliation></author><author><name sortKey="Yagisawa, Takashi" sort="Yagisawa, Takashi" uniqKey="Yagisawa T" first="Takashi" last="Yagisawa">Takashi Yagisawa</name><affiliation wicri:level="1"><nlm:affiliation>Surgical Branch, Institute of Kidney Diseases, Jichi Medical University Hospital, Shimotsuke, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Surgical Branch, Institute of Kidney Diseases, Jichi Medical University Hospital, Shimotsuke</wicri:regionArea><wicri:noRegion>Shimotsuke</wicri:noRegion></affiliation></author></analytic><series><title level="j">Transplant infectious disease : an official journal of the Transplantation Society</title><idno type="eISSN">1399-3062</idno><imprint><date when="2019" type="published">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged (MeSH)</term><term>Epstein-Barr Virus Infections (drug therapy)</term><term>Everolimus (therapeutic use)</term><term>Herpesvirus 4, Human (MeSH)</term><term>Humans (MeSH)</term><term>Immunosuppressive Agents (therapeutic use)</term><term>Kidney Transplantation (adverse effects)</term><term>Lymphoproliferative Disorders (drug therapy)</term><term>Lymphoproliferative Disorders (virology)</term><term>Male (MeSH)</term><term>Postoperative Complications (drug therapy)</term><term>Remission Induction (MeSH)</term><term>Transplant Recipients (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Complications postopératoires (traitement médicamenteux)</term><term>Herpèsvirus humain de type 4 (MeSH)</term><term>Humains (MeSH)</term><term>Immunosuppresseurs (usage thérapeutique)</term><term>Induction de rémission (MeSH)</term><term>Infections à virus Epstein-Barr (traitement médicamenteux)</term><term>Mâle (MeSH)</term><term>Receveurs de transplantation (MeSH)</term><term>Sujet âgé (MeSH)</term><term>Syndromes lymphoprolifératifs (traitement médicamenteux)</term><term>Syndromes lymphoprolifératifs (virologie)</term><term>Transplantation rénale (effets indésirables)</term><term>Évérolimus (usage thérapeutique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Everolimus</term><term>Immunosuppressive Agents</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Kidney Transplantation</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Epstein-Barr Virus Infections</term><term>Lymphoproliferative Disorders</term><term>Postoperative Complications</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Transplantation rénale</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Complications postopératoires</term><term>Infections à virus Epstein-Barr</term><term>Syndromes lymphoprolifératifs</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Immunosuppresseurs</term><term>Évérolimus</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Syndromes lymphoprolifératifs</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Lymphoproliferative Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Herpesvirus 4, Human</term><term>Humans</term><term>Male</term><term>Remission Induction</term><term>Transplant Recipients</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Herpèsvirus humain de type 4</term><term>Humains</term><term>Induction de rémission</term><term>Mâle</term><term>Receveurs de transplantation</term><term>Sujet âgé</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Post-transplant lymphoproliferative disorder (PTLD) is a fatal complication of transplantation. There is no clear consensus on the treatment of PTLD. In most cases, the pathogenetic mechanism of PTLD involves the Epstein-Barr virus (EBV). We report the case of an elderly kidney transplant recipient who developed EBV-positive monomorphic T-cell PTLD 14 years after transplantation. Conversion from conventional immunosuppressants to everolimus induced complete remission of PTLD accompanied by a decrease in blood EBV-DNA level without chemotherapy.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31102475</PMID><DateCompleted><Year>2019</Year><Month>12</Month><Day>12</Day></DateCompleted><DateRevised><Year>2020</Year><Month>01</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-3062</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>4</Issue><PubDate><Year>2019</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Transplant infectious disease : an official journal of the Transplantation Society</Title><ISOAbbreviation>Transpl Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Remission of Epstein-Barr virus-positive post-transplant lymphoproliferative disorder by conversion to everolimus in a kidney transplant recipient.</ArticleTitle><Pagination><MedlinePgn>e13116</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/tid.13116</ELocationID><Abstract><AbstractText>Post-transplant lymphoproliferative disorder (PTLD) is a fatal complication of transplantation. There is no clear consensus on the treatment of PTLD. In most cases, the pathogenetic mechanism of PTLD involves the Epstein-Barr virus (EBV). We report the case of an elderly kidney transplant recipient who developed EBV-positive monomorphic T-cell PTLD 14 years after transplantation. Conversion from conventional immunosuppressants to everolimus induced complete remission of PTLD accompanied by a decrease in blood EBV-DNA level without chemotherapy.</AbstractText><CopyrightInformation>© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nanmoku</LastName><ForeName>Koji</ForeName><Initials>K</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-3987-4832</Identifier><AffiliationInfo><Affiliation>Surgical Branch, Institute of Kidney Diseases, Jichi Medical University Hospital, Shimotsuke, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shinzato</LastName><ForeName>Takahiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Surgical Branch, Institute of Kidney Diseases, Jichi Medical University Hospital, Shimotsuke, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kubo</LastName><ForeName>Taro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Surgical Branch, Institute of Kidney Diseases, Jichi Medical University Hospital, Shimotsuke, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimizu</LastName><ForeName>Toshihiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Surgical Branch, Institute of Kidney Diseases, Jichi Medical University Hospital, Shimotsuke, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yagisawa</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Surgical Branch, Institute of Kidney Diseases, Jichi Medical University Hospital, Shimotsuke, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>05</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Transpl Infect Dis</MedlineTA><NlmUniqueID>100883688</NlmUniqueID><ISSNLinking>1398-2273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>9HW64Q8G6G</RegistryNumber><NameOfSubstance UI="D000068338">Everolimus</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020031" MajorTopicYN="N">Epstein-Barr Virus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068338" MajorTopicYN="N">Everolimus</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004854" MajorTopicYN="N">Herpesvirus 4, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016030" MajorTopicYN="N">Kidney Transplantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008232" MajorTopicYN="N">Lymphoproliferative Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012074" MajorTopicYN="Y">Remission Induction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066027" MajorTopicYN="N">Transplant Recipients</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Epstein-Barr virus-DNA</Keyword><Keyword MajorTopicYN="N">kidney transplantation</Keyword><Keyword MajorTopicYN="N">mammalian target of rapamycin inhibitor</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>04</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>04</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>05</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31102475</ArticleId><ArticleId IdType="doi">10.1111/tid.13116</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Taylor AL, Marcus R, Bradley JA. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol. 2005;56(1):155-167.</Citation></Reference><Reference><Citation>Allen U, Hebert D, Moore D, et al. Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplant recipients, 1988-97: a Canadian multi-centre experience. Pediatr Transplant. 2001;5(3):198-203.</Citation></Reference><Reference><Citation>Hoshida Y, Li T, Dong Z, et al. Lymphoproliferative disorders in renal transplant patients in Japan. Int J Cancer. 2001;91(6):869-875.</Citation></Reference><Reference><Citation>Nourse JP, Jones K, Gandhi MK. Epstein-Barr virus-related post-transplant lymphoproliferative disorders: pathogenetic insights for targeted therapy. Am J Transplant. 2011;11(5):888-895.</Citation></Reference><Reference><Citation>Pascual J, Royuela A, Fernández AM, et al. Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients. Transpl Infect Dis. 2016;18(6):819-831.</Citation></Reference><Reference><Citation>Majewski M, Korecka M, Kossev P, et al. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci USA. 2000;97(8):4285-4290.</Citation></Reference><Reference><Citation>Majewski M, Korecka M, Joergensen J, et al. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation. 2003;75(10):1710-1717.</Citation></Reference><Reference><Citation>Rajakariar R, Bhattacharyya M, Norton A, et al. Post transplant T-cell lymphoma: a case series of four patients from a single unit and review of the literature. Am J Transplant. 2004;4(9):1534-1538.</Citation></Reference><Reference><Citation>Al-Mansour Z, Nelson BP, Evens AM. Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. Curr Hematol Malig Rep. 2013;8(3):173-183.</Citation></Reference><Reference><Citation>Green M, Michaels MG. Epstein-Barr virus infection and posttransplant lymphoproliferative disorder. Am J Transplant. 2013;13(suppl 3):41-54.</Citation></Reference><Reference><Citation>Pascual J. Post-transplant lymphoproliferative disorder-the potential of proliferation signal inhibitors. Nephrol Dial Transplant. 2007;22(suppl 1):i27-35.</Citation></Reference><Reference><Citation>Brennan DC, Aguado JM, Potena L, et al. Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms. Rev Med Virol. 2013;23(2):97-125.</Citation></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Japon</li></country></list><tree><country name="Japon"><noRegion><name sortKey="Nanmoku, Koji" sort="Nanmoku, Koji" uniqKey="Nanmoku K" first="Koji" last="Nanmoku">Koji Nanmoku</name></noRegion><name sortKey="Kubo, Taro" sort="Kubo, Taro" uniqKey="Kubo T" first="Taro" last="Kubo">Taro Kubo</name><name sortKey="Shimizu, Toshihiro" sort="Shimizu, Toshihiro" uniqKey="Shimizu T" first="Toshihiro" last="Shimizu">Toshihiro Shimizu</name><name sortKey="Shinzato, Takahiro" sort="Shinzato, Takahiro" uniqKey="Shinzato T" first="Takahiro" last="Shinzato">Takahiro Shinzato</name><name sortKey="Yagisawa, Takashi" sort="Yagisawa, Takashi" uniqKey="Yagisawa T" first="Takashi" last="Yagisawa">Takashi Yagisawa</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000248 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000248 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= RapamycinFungusV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:31102475
|texte= Remission of Epstein-Barr virus-positive post-transplant lymphoproliferative disorder by conversion to everolimus in a kidney transplant recipient.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:31102475" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a RapamycinFungusV1
| This area was generated with Dilib version V0.6.38. |  |